Related to Failure of Anticoagulant Prompts BioInvent to Seek $2.2M Cost Cuts

• Sanofi and Genzyme Report Positive Data from Pivotal Trial Comparing Alemtuzumab with Rebif in MS
  
• Amgen Pays $10M Up Front in Cancer Deal with Micromet
  
• EC Clears HGS and GSK’s Systemic Lupus Erythematosus Antibody Therapy Benlysta
  
• Amgen’s Xgeva Approved by EC for Treating SREs in Adults with Solid Tumor-Related Bone Metastases
  
• FDA Approves AstraZeneca’s Antiplatelet Drug
  
• Sorrento Wins Second NIAID Grant of $600K to Develop Qourum Quenching Antibacterial
  
• French Firm AAA Acquires Dompe’s Radiolabeled mAb for Ovarian Cancer Therapy
  
• EC Approves Roche’s RoActemra for Treating Active Systemic Juvenile Idiopathic Arthritis
  
• Genentech Takes Another Shot at Convincing FDA to Maintain Avastin’s Metastatic Breast Cancer Approval
  
• Oncobiologics and Fox Chase Cancer Center Ally to Develop Cancer Therapy Platform
  
• FDA Issues Novartis with CRL Requesting Additional Safety Data on Gouty Arthritis Drug
  
• F-Star and Merck Serono Sign Potential €492M Deal for Antibody-Derived Therapeutics
  
• Sucampo Taps Numab for Antibody Discovery and Development Expertise
  
• Swiss Institute Spins Out Human mAb Therapeutics Firm
  
• Teva Invests $19M More in CureTech After Positive Phase II DLBCL Data
  
• Chinese Firms ChemPartner and Hengrui Collaborate on Therapeutic mAbs
  
• FDA Gives Amgen’s Prolia the Go-Ahead in Two Cancer Therapy-Induced Bone Loss Indications
  
• BMS and Ono Expand Cancer Antibody Deal and Agree to Partner Orencia in Japan
  
• MedImmune Inks Deal for Pfizer's Anticancer mAb Therapeutic
  
• X-Body BioSciences and Tanabe Research Labs Team Up to Develop mAbs for Autoimmune Diseases